Literature DB >> 27062800

[A multi-center, randomized, double-blind clinical study on Bushen Huoxue in treatment of ovulatory dysfunction caused infertility].

Kun Ma, Yan-feng Liu, Jun-qin He, Min Li, Jing Shan.   

Abstract

OBJECTIVE: The multi-center, randomized, double-blind, double-simulated and positive-control trial was used to verify the contribution degree of Bushen Huoxue for the treatment of ovulatory dysfunction caused infertility, which provided scientific basis for clinical treatment.
METHOD: According to diagnostic, inclusion and exclusion criteria, we observed 349 patients which were divided into the treated group (n = 177, treated with Bushen Huoxue ricipe) and control group (n = 172, treated with clomiphene). Ovulation rate, pregnancy rate, clinical effective rate of traditional Chinese medicine, endometrium and diameter of dominant follicle were observed. Serum reproductive endocrine hormones were assayed before and after treatment. RESULT: The treated group showed ovulation rate of 69.34%, with pregnancy rate of 41.35%. The clinical effective rate of treated group and control group were 91.73% and 80.77%. There was remarkable difference in endometrium (P < 0.05) and remarkbale difference in sex hormones PRL and E₂in treated group at prior-treatment and post-treatment (P < 0.05). No adverse effects were found in the experiment. Security indicators did not show abnormal change.
CONCLUSION: The comparison between the two groups showed that the treated group was significantly different from control group in the pregnancy rate (P < 0.05), without notable difference in ovulation rate. There was significant difference in clinical effective rate between the treated group and control group. Both the two groups could contribute to the mature development and discharge of the follicles. The growth of endometrium and endometrial receptivity in the treated group were higher than control group. The treated group has regulatory effect on PRL and E₂.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 27062800

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  6 in total

Review 1.  A general description for Chinese medicine in treating premature ovarian failure.

Authors:  Jing Lin; Xue-Lian Li; Hui Song; Qian Li; Ming-Yan Wang; Xue-Min Qiu; Da-Jin Li; Ling Wang
Journal:  Chin J Integr Med       Date:  2017-03-07       Impact factor: 1.978

2.  Bushen Huoxue recipe attenuates early pregnancy loss via activating endometrial COX2-PGE2 angiogenic signaling in mice.

Authors:  Yufan Song; Fanru Zhou; Xiujuan Tan; Xia Liu; Jiahui Ding; Chu Zhang; Fan Li; Wenxin Zhu; Wenwen Ma; Runan Hu; Mingmin Zhang
Journal:  BMC Complement Med Ther       Date:  2021-01-14

3.  Bushen Culuan Decoction Ameliorates Premature Ovarian Insufficiency by Acting on the Nrf2/ARE Signaling Pathway to Alleviate Oxidative Stress.

Authors:  Yanxia Chen; Xiaodi Fan; Kun Ma; Kaili Wang; Caidie Tian; Min Li; Linjuan Gong
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.988

4.  The effect of Bushen Culuan Decoction on anovulatory infertile women among 6 different diseases: a study protocol for a randomized, double-blinded, positively controlled, adaptive multicenter clinical trial.

Authors:  Kun Ma; Yun Shi; Junqin He; Xiuxiang Teng; Rongyu Wang; Guohua Wang; Yanan Yu; Yanxia Chen; Linjuan Gong; Yuan Yuan; Huixian Zhang; Bochao Yuan; Chenhui Zhang
Journal:  Trials       Date:  2022-07-08       Impact factor: 2.728

5.  Bushen Huoxue Recipe Alleviates Implantation Loss in Mice by Enhancing Estrogen-Progesterone Signals and Promoting Decidual Angiogenesis Through FGF2 During Early Pregnancy.

Authors:  Jiahui Ding; Xiujuan Tan; Kunkun Song; Wenwen Ma; Jing Xiao; Yufan Song; Mingmin Zhang
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

6.  Bushen Tiaojing (II and III) Decoctions Activate MAPK14 and MAPK3/1 to Promote the Expression of Cumulus Expansion-Related Factors in Mice.

Authors:  Xiao Liang; Xue Tong; Hui-Lan Du; Ming He; Yu Zhang; Yan-Cang Duan
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-18       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.